A holding company controlled by JLL will acquire BioClinica, of Newtown, through a cash tender offer at $7.25 per share.
Shares of the publicly traded BioClinica were up 19 percent, of $1.17, at $7.22 in morning trading.
In addition, JLL will acquire Princeton-based CoreLab Partners Inc., a provider of services to the biopharmaceutical industry, and combine it with BioClinica.
BioClinica president and CEO Mark L. Weinstein would lead the resulting company.
Here is a link to the statement announcing the transaction.